Therapeutic Advances in Neurological Disorders

• Management of Sexual Dysfunction in Parkinson's Disease Sexual dysfunction is common and often under-recognized in patients with Parkinson's disease. How should it be treated?
  Therapeutic Advances in Neurological Disorders, November 2011
• Optimizing Outcomes in Multiple Sclerosis A panel of Latin American neurologists presents consensus guidelines for the diagnosis and treatment of multiple sclerosis in that region.
  Therapeutic Advances in Neurological Disorders, November 2011
• Response to Rituximab in Refractory Myasthenia Gravis This study assesses the effectiveness of the monoclonal antibody rituximab in the treatment of myasthenia gravis. Could it be beneficial for those patients refractory to other therapies?
  Therapeutic Advances in Neurological Disorders, October 2011
• Interferon Beta Therapies for Relapsing-Remitting MS Interferon beta preparations are the most widely used initial therapies prescribed for patients with relapsing-remitting MS. How do the three currently available formulations compare?
  Therapeutic Advances in Neurological Disorders, September 2011
• Approaches to the Treatment of Paraneoplastic Encephalitis Immune-mediated, or paraneoplastic encephalitis, can present with symptoms of seizure, amnesia, and mental changes--even psychosis. How is it best treated?
  Therapeutic Advances in Neurological Disorders, August 2011
• Disease-Modifying Treatments for Alzheimer's Disease Several disease-modifying drugs are now available which claim to block the progression of Alzheimer's disease. How effective are they--and where should we go from here?
  Therapeutic Advances in Neurological Disorders, July 2011
• Nonconvulsive Status Epilepticus in the ICU Setting Nonconvulsive status epilepticus presents a diagnostic challenge in the ICU, particularly in comatose patients. This review examines clinical criteria and EEG patterns that may give important clues.
  Therapeutic Advances in Neurological Disorders, July 2011
• Symptomatic Therapy in Multiple Sclerosis There are a myriad of symptoms and comorbidities associated with MS which are frequently ignored or dismissed, and which greatly affect quality of life. Many of these are treatable.
  Therapeutic Advances in Neurological Disorders, June 2011
• Treatment Approaches for Neuromyelitis Optica Immunosuppressive drugs are becoming the therapy of choice in neuromyelitis optica. This review summarizes current treatment options and proposes new therapeutic strategies for the future.
  Therapeutic Advances in Neurological Disorders, May 2011
• Diagnosis and Treatment of Myoclonic Disorders Myoclonus is a clinical sign which can manifest in a wide variety of disorders. To optimize treatment, it is critical to identify the underlying cause.
  Therapeutic Advances in Neurological Disorders, April 2011
• Treatment Strategies for Tics in Tourette Syndrome This overview of Tourette syndrome summarizes a wide variety of treatment options, including pharmacological, surgical, and emerging technologies such as rTMS and deep brain stimulation.
  Therapeutic Advances in Neurological Disorders, March 2011
• Treatment of Walking Impairment in MS With Dalfampridine Walking impairment is among the most disabling problems associated with multiple sclerosis. Can the potassium channel blocker dalfampridine help?
  Therapeutic Advances in Neurological Disorders, March 2011
• Evolving Expectations Around Early Management of Multiple Sclerosis It's never too early to starting disease-modifying treatment for multiple sclerosis, once the diagnosis is reasonably formulated.
  Therapeutic Advances in Neurological Disorders, February 2011
• Quetiapine in the Treatment of Psychosis in Parkinson's Disease Delusions and hallucinations are common non-motor features of Parkinson's disease. The atypical antipsychotic quetiapine showed early promise for relief, but is it as effective as the alternatives?
  Therapeutic Advances in Neurological Disorders, January 2011
• Natalizumab in Pediatric Multiple Sclerosis Patients Is natalizumab, a recombinant, humanized monoclonal antibody, safe and effective in pediatric MS patients?
  Therapeutic Advances in Neurological Disorders, December 2010
• Atacicept: Targeting B Cells in Multiple Sclerosis There's an increasing body of evidence for the involvement of B-cells and autoantibodies in the pathology of MS, providing rationale for B-cell targeted treatment.
  Therapeutic Advances in Neurological Disorders, October 2010
• Therapeutic Strategies in Childhood Multiple Sclerosis Although juvenile-onset MS accounts for up to 10% of patients, the use of medications is mainly based on results on clinical trials in adults.. What therapeutic approach should be taken?
  Therapeutic Advances in Neurological Disorders, October 2010
• Antiviral Agents in Alzheimer's Disease: Hope for the Future? This review posits a causal relationship between the neurotropic virus HSV-1 and Alzheimer's disease, making way for an antiviral approach to therapy for AD.
  Therapeutic Advances in Neurological Disorders, October 2010
• Therapeutic Developments in Spinal Muscular Atrophy Recent advances and a greater understanding of its etiology provide cautious optimism that effective treatments for spinal muscular atrophy will emerge.
  Therapeutic Advances in Neurological Disorders, October 2010
• Chemotherapeutics in the Treatment of Multiple Sclerosis An overview of currently approved and off-label treatment options for multiple sclerosis, as well as new therapies under investigation.
  Therapeutic Advances in Neurological Disorders, September 2010